Stock LAB B GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V.
Add to a list
To use this feature you must be a member
Log inSign up

Company Genomma Lab Internacional, S.A.B. de C.V.

Equities

LAB B

MX01LA010006

Pharmaceuticals

End-of-day quote Mexican S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
16.3 MXN +3.16% Intraday chart for Genomma Lab Internacional, S.A.B. de C.V. +8.23% +15.11%
04-25 Transcript : Genomma Lab Internacional, S.A.B. de C.V., Q1 2024 Earnings Call, Apr 25, 2024
04-24 Genomma Lab Internacional, S.A.B. de C.V. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Business Summary

Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Company’s product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.

Number of employees: 1,783

Sales per Business

MXN in Million2021Weight2022Weight Delta
Pharmaceutical Products and Personal Care Products
100.0 %
15,487 100.0 % 16,820 100.0 % +8.61%

Sales per region

MXN in Million2021Weight2022Weight Delta
International
59.9 %
9,024 58.3 % 10,069 59.9 % +11.59%
Mexico
40.1 %
6,464 41.7 % 6,751 40.1 % +4.44%

Managers

Managers TitleAgeSince
Marco Sparvieri CEO
 Chief Executive Officer - -
Rodrigo Alonso Herrera Aspra FOU
 Founder - 29/10/96
Antonio Zamora Galland DFI
 Director of Finance/CFO - -
Jorge Luis Brake Valderrama BRD
 Director/Board Member - 09/09/18
Marco Francisco Forastieri Muñoz BRD
 Director/Board Member - 28/03/12
Alejandro Bastón Patiño IRO
 Public Communications Contact - 30/09/08

Members of the board

Members of the board TitleAgeSince
Burkhard Wittek BRD
 Director/Board Member 70 17/04/18
Juan Carlos Gavito Aspe BRD
 Director/Board Member - -
Rodrigo Alonso Herrera Aspra FOU
 Founder - 29/10/96
Sabrina Lucila Herrera Aspra BRD
 Director/Board Member - 31/12/97
Juan Alonso BRD
 Director/Board Member - -
Marco Francisco Forastieri Muñoz BRD
 Director/Board Member - 28/03/12
Jorge Luis Brake Valderrama BRD
 Director/Board Member - 09/09/18
Carlos Javier Vara Alonso BRD
 Director/Board Member - 17/04/18
Javier Vale Castilla BRD
 Director/Board Member - -
Ignacio Gonzalez Rodriguez BRD
 Director/Board Member - -

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,020,000,000 712,097,600 ( 69.81 %) 74,855,920 ( 7.339 %) 69.81 %

Shareholders

NameEquities%Valuation
MFS International (UK) Ltd.
2.533 %
25,839,330 2.533 % 25 M $
Skagen AS (Investment Management)
2.176 %
22,200,000 2.176 % 21 M $
Lemanik Asset Management SA
1.555 %
15,863,042 1.555 % 15 M $
BlackRock México Operadora SA de CV SOFI
1.370 %
13,976,395 1.370 % 13 M $
Operadora de Fondos Banorte SA de CV
1.166 %
11,896,415 1.166 % 11 M $
Denker Capital (Pty) Ltd.
0.8247 %
8,412,284 0.8247 % 8 M $
Swedbank Robur Fonder AB
0.6114 %
6,236,714 0.6114 % 6 M $
Old Mutual Investment Group (Pty) Ltd.
0.4000 %
4,079,696 0.4000 % 4 M $
North of South Capital LLP
0.3977 %
4,056,696 0.3977 % 4 M $
Westwood International Advisors, Inc.
0.2807 %
2,863,361 0.2807 % 3 M $

Company contact information

Genomma Lab Internacional SAB de CV

Avendia Antonio Dovalí Jaime, 70 Torre C, Piso 2, Despacho A

01210, Mexico City

+

http://www.genommalab.com
address Genomma Lab Internacional, S.A.B. de C.V.(LAB B)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Genomma Lab Internacional, S.A.B. de C.V.

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
16.3 MXN
Average target price
20.6 MXN
Spread / Average Target
+26.38%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. Stock Genomma Lab Internacional, S.A.B. de C.V.
+15.11% 882M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.55% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.54% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.35% 332B
ABBVIE INC. Stock AbbVie Inc.
+2.94% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.42% 231B
NOVARTIS AG Stock Novartis AG
+4.71% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
AMGEN INC. Stock Amgen Inc.
-5.12% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. LAB B Stock
  4. Company Genomma Lab Internacional, S.A.B. de C.V.